RSV604 is primarily researched for its potential application in the treatment of respiratory syncytial virus (RSV) infections. It functions as an antiviral agent by targeting the virus's replication process, thereby inhibiting its ability to spread within the host. This makes it a promising candidate for managing RSV, particularly in vulnerable populations such as infants, the elderly, and immunocompromised individuals. Clinical studies are ongoing to evaluate its efficacy and safety, with the aim of developing it as a therapeutic option to reduce the severity and duration of RSV infections. Additionally, its potential use in combination therapies is being explored to enhance overall treatment outcomes.